TYRA News and Press, Tyra Biosciences Inc. From 06/30/22

Gainers: NeuroSense Therapeutics ( NRSN ) +53% . Rapid Micro Biosystems ( RPID ) +36% . Burning Rock Biotech ( BNR ) +15% . Tyra Biosciences ( TYRA ) +7% . Addex Therapeutics ( ADXN ) +5% . Losers: Renalytix ( RNLX ) -40% ...

Gainers: Endo International plc (ENDP) +95%. Agile Therapeutics (AGRX) +66%. Kezar Life Sciences (KZR) +53%. Decibel Therapeutics (DBTX) +25%. Ceragon Networks (CRNT) +23%. InflaRx (IFRX) +20%. Sutro Biopharma (STRO) +19%. Tyra Biosciences (TYRA) +17%. Oasis Petroleum (OAS) +16%. Biotricity (...

H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Tyra Biosciences (TYRA) with a Buy rating and $12 price target. The biotech company focused on development of therapies to combat acquired drug resistance across various cancers has a proprietary in-house discovery platform an...

Tyra Biosciences press release (NASDAQ:TYRA): Q1 GAAP EPS of -$0.36 misses by $0.16. As of March 31, 2022, TYRA had cash and cash equivalents of $292.5 million. For further details see: Tyra Biosciences GAAP EPS of -$0.36 misses by $0.16

Tyra Biosciences Reports First Quarter 2022 Financial Results and Highlights PR Newswire -Pipeline on-track; INDs to be filed for TYRA-300 and TYRA-200 in 2022- -Well-capitalized with cash and cash equivalents of $292.5 million as of Q1 2022- CARL...

The following slide deck was published by Tyra Biosciences, Inc. in conjunction with this event. For further details see: Tyra Biosciences (TYRA) Investor Presentation - Slideshow

Tyra Biosciences press release (NASDAQ:TYRA): Q4 GAAP EPS of -$0.24. Q4 Net loss $9.9M For further details see: Tyra Biosciences GAAP EPS of -$0.24

Tyra Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights -Pipeline on-track; INDs expected to be filed for TYRA-300 and TYRA-200 in 2022- -Strengthened organization with key appointment to clinical team- -Well-capitalized with cash and ...

Tyra Biosciences to Participate in Cowen 42nd Annual Healthcare Conference PR Newswire CARLSBAD, Calif. , Feb. 22, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome t...

Tyra Biosciences (TYRA +14.0%) owner Boxer Capital bought 125,000 shares at $13.12 per share. The transaction was worth $1.6M. This brings his total share holding to ~6.44M shares Form 4 The stock has a market cap of $497.1M. For further details see: Tyra Biosciences surges 14% as owner...